3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
109
Carcinoma, Non-Small-Cell Lung
96
Prostatic Neoplasms
60
Multiple Myeloma
46
Neoplasms
38
Neoplasm Metastasis
33
Ovarian Neoplasms
26
Urinary Bladder Neoplasms
24
Melanoma
24
Lung Neoplasms
22
Recurrence
21
Parkinson Disease 4, Autosomal Dominant Lewy Body
21
Leukemia, Lymphocytic, Chronic, B-Cell
21
Colorectal Neoplasms
21
Carcinoma, Renal Cell
20
Leukemia, Myeloid, Acute
17
Carcinoma, Hepatocellular
17
Triple Negative Breast Neoplasms
16
Lymphoma, Non-Hodgkin
16
Stomach Neoplasms
15
Nasopharyngeal Carcinoma
15
Lymphoma
14
Squamous Cell Carcinoma of Head and Neck
13
Small Cell Lung Carcinoma
13
Fallopian Tube Neoplasms
12
Colonic Neoplasms
12
Carcinoma
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Lymphoma, Large B-Cell, Diffuse
11
Lymphoma, Follicular
11
Interventions
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Active not recruiting
×
Muscle-invasive Bladder Cancer
×
Clear all
NCT04660344
2026-03-27
IMvigor011
Hoffmann-La Roche
Phase 3
Active not recruiting
761 enrolled
1 FDA